Is there a role for isolated limb perfusion with tumor necrosis factor in patients with melanoma?

Annals of Surgical Oncology

Volumn 11, Issue 2, 2004, Pages 119-121

  De Wilt, Johannes H W ^a   Thompson, John F ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CRYOTHERAPY; DIATHERMY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; HUMAN; LIMB AMPUTATION; LIMB PERFUSION; LIMB SALVAGE; MELANOMA; METASTASIS; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; SARCOMA; SIDE EFFECT; TUMOR NECROSIS; TUMOR VOLUME; VACCINATION; NOTE; PATHOLOGY; REGIONAL PERFUSION; SKIN TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MELANOMA; MELPHALAN; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342531719     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.12.932     Document Type: Editorial

References (23)

1. Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004;11:173-7.
2. Creech O, Krementz ET, Ryan RF, Winblad JW. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32.
3. Eggermont AM, van Geel AN, de Wilt JH, ten Hagen TL. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am 2003;83:371-84.
4. Kroon BBR, Fraker DL, Vrouenraets BC, Thompson JF. Isolated limb perfusion: results and complications. In: Thompson JF, Morton DL, Kroon BB, eds. Textbook of Melanoma. London: Martin Dunitz, 2004:410-28.
5. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
6. Klaase JM, Kroon BBR, Benckhuijsen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616-21.
7. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64; discussion 764-5.
8. Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 2001;8:564-5.
9. McKay A, Byrne DS. Recurrent limb melanoma: treatments other than isolated limb perfusion and infusion. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz, 2004:443-8.
10. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg Clin North Am 2003;83:343-70.
11. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47.
12. Thompson JP, Kam PCA, de Wilt JHW, Lindner P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz, 2004:429-437.
13. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-74.
14. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995-7.
15. de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999;80:161-6.
16. Fraker DL, Alexander HR, Ross M. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 2002;9:58.
17. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906-12.
18. Olieman AF, van Ginkel RJ, Hoekstra HJ, et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64-9.
19. van Etten B, de Vries MR, van Ijken MGA, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003;88:314-9.
20. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
21. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.
22. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.
23. Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084-90.